JAMA
August 31, 2023
Charles L Raison, Gerard Sanacora, Joshua Woolley et al.
493 citations
A single 25-mg dose of synthetic psilocybin, administered with psychological support, produced a clinically significant and sustained reduction in depressive symptoms and functional disability over 43 days in adults with major depressive disorder. In a phase 2 trial of 104 participants, those receiving psilocybin showed a mean 12.3-point greater improvement on the Montgomery-Asberg Depression Rating Scale at day 43 compared with those receiving a niacin placebo. Psilocybin also improved daily functioning and led to more sustained response, though not remission. No serious adverse events occurred, but psilocybin was associated with more overall and severe adverse events.
JAMA
October 21, 2025
Reid Robison, Robert Barrow, Craig Conant et al.
22 citations
A single dose of MM120 (lysergide D-tartrate) reduces anxiety in a dose-dependent way in adults with moderate to severe generalized anxiety disorder. In a phase 2b randomized, double-blind, placebo-controlled trial with 198 participants, the 100-µg and 200-µg doses produced significantly greater reductions in Hamilton Anxiety Rating Scale scores at 4 weeks than placebo, with differences of -5.0 and -6.0 points, respectively. Lower doses (25 µg and 50 µg) did not differ from placebo. Common side effects included visual perceptual changes and nausea, which increased with dose.
Frontiers in Psychiatry
February 9, 2023
Anya Ragnhildstveit, Miriam Kaiyo, Matthew Brian Snyder et al.
10 citations
A 28-year-old woman with complex dissociative posttraumatic stress disorder (D-PTSD) underwent ten sessions of cannabis-assisted psychotherapy (CAP) over five months, combined with cognitive behavioral therapy. After treatment, her pathological dissociation score, measured by the Multidimensional Inventory of Dissociation, dropped by 98.5%, and she no longer met criteria for D-PTSD. She also experienced reduced cognitive distractibility, less emotional suffering, and improved psychosocial functioning. The patient has maintained these gains for over two years. The authors suggest CAP, which produced subjective effects similar to psychedelics like psilocybin and ketamine, warrants further research as a potential treatment for D-PTSD.